Official Title
Single Center Prospective Controlled Follow-up Study of COVID-19 Patients in the District Konstanz (FSC19-KN)
Brief Summary

This is a prospective single-center study for the follow-up of SARS-CoV-2 positive patients in the district of Konstanz (LKN). As part of the coronavirus pandemic, patients with SARS-CoV-2 infection are currently being treated in the clinics of the LKN's health network at the Singen (Hegau-Bodensee Clinic) and Konstanz (Konstanz Clinic) locations. So far, there is little data on the long-term effects of SARS-CoV-2 infection. As part of this study, the disease progression of these patients will be monitored. Study objective: Prospective, controlled follow-up observation of SARS-CoV-2 positive patients regarding their secondary diseases and quality of life.

Active, not recruiting
SARS-CoV-2 Positive Patients
Eligibility Criteria

Inclusion Criteria:

A Inclusion Criteria of SARS-CoV-2 positive patients:

Patient must meet all of the following criteria.

1. Positive test for SARS-CoV-2 by PCR

2. Signed informed consent and privacy policy

B Inclusion Criteria of the control Group:

Volunteer must meet all of the following criteria.

1. No contact to SARS-CoV-2 positive patients

2. negative SARS-CoV-2 antibody test

3. Signed informed consent and privacy policy

Exclusion Criteria:

Patient/Volunteer will be excluded if any of the following conditions apply:

1. Patient/Volunteer age < 18 years

2. Patient/Volunteer who are unable to read the information and understand the nature of
the study

3. Patient/Volunteer participate in any other clinical study

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Germany
Locations

Hegau-Bodensee-Klinikum Singen
Singen, Baden-Württemberg, Germany

Marc Kollum, PD Dr. med., Principal Investigator
Hegau-Bodensee-Klinikum Singen

Department of Health and Human Services
NCT Number
Keywords
COVID-19 virus disease
SARS-CoV-2
hospitalization
Quality of Life
EQ-5D-5L
Cardiomyopathy, Kansas City (KCCQ-12)
MeSH Terms
COVID-19